scispace - formally typeset
Open AccessJournal ArticleDOI

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

Mark A. Dickson, +13 more
- 01 Jun 2013 - 
- Vol. 31, Iss: 16, pp 2024-2028
TLDR
Treatment with theCDK4 inhibitor PD0332991 was associated with a favorable progression-free rate in patients with CDK4-amplified and RB-expressing WDLS/DDLS who had progressive disease despite systemic therapy.
Abstract: 
Purpose CDK4 is amplified in 90% of well-differentiated (WDLS) and dedifferentiated liposarcomas (DDLS). The selective cyclin-dependent kinase 4 (CDK4)/CDK6 inhibitor PD0332991 inhibits growth and induces senescence in cell lines and xenografts. In a phase I trial of PD0332991, several patients with WDLS or DDLS experienced prolonged stable disease. We performed an open-label phase II study to determine the safety and efficacy of PD0332991 in patients with advanced WDLS/DDLS.

read more

Content maybe subject to copyright    Report

Citations
More filters

Atypical Lipomatous Tumor/Well Differentiated Liposarcoma: a Borderline Malignancy Tumor

Cornelia Nitipir, +7 more
TL;DR: A large number of patients in this study had no prior history of cancer, and the results confirmed that once the cancer is diagnosed, the prognosis is good for the patient’s health.
Journal ArticleDOI

Updated Review and Clinical Recommendations for the Diagnosis and Treatment of Patients with Retroperitoneal Sarcoma by the Spanish Sarcoma Research Group (GEIS)

R. Álvarez Álvarez, +19 more
- 01 Jun 2023 - 
TL;DR: In this article , the authors provide an updated review on the management of retroperitoneal sarcoma and issue clear and concise recommendations for the treatment of the main clinical situations encountered in this disease.
Journal ArticleDOI

Thérapeutiques ciblées dans les tumeurs de l'os et des tissus mous : vers une prise en charge individualisée

A. Italiano
- 01 Apr 2016 - 
TL;DR: Targeting the molecular anomalies which are characteristic of sarcomas could lead to improved patient survival, as has been demonstrated for gastrointestinal stroma tumours and dermatofibrosarcomas.

TrabectedinandtheL-Sarcomas:ADecade-LongOdyssey

Gary K. Schwartz
Journal ArticleDOI

Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance

Jeff Rytlewski, +4 more
- 04 Jan 2022 - 
TL;DR: Clinical attempts at modulating epigenetics in sarcoma are reviewed, as well as potential implications of these studies, and epigenetic targets to reverse and delay chemotherapy resistance are discussed.
References
More filters
Journal ArticleDOI

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Elizabeth Eisenhauer, +15 more
- 01 Jan 2009 - 
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Book

Statistical methods for rates and proportions

Joseph L. Fleiss
TL;DR: In this paper, the basic theory of Maximum Likelihood Estimation (MLE) is used to detect a difference between two different proportions of a given proportion in a single proportion.
Journal ArticleDOI

Statistical Methods for Rates and Proportions.

B. S. Everitt, +1 more
- 01 Sep 1973 - 
Journal Article

[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].

Hirokazu Watanabe, +9 more
- 01 Dec 2009 - 
TL;DR: This paper is an overview of the new response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), with a focus on updated contents.
Journal Article

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, +10 more
- 01 Nov 2004 - 
TL;DR: Results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net reduction in tumor burden in some tumors.
Related Papers (5)

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, +10 more
- 01 Nov 2004 - 

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Richard S. Finn, +11 more
- 29 Oct 2009 - 

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

Winette T. A. van der Graaf, +22 more
- 19 May 2012 - 

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Richard S. Finn, +17 more
- 01 Jan 2015 - 

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

Stefan Sleijfer, +12 more
- 01 Jul 2009 -